Windtree Therapeutics Inc
Company Profile
Business description
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Contact
2600 Kelly Road
Suite 100
WarringtonPA18976-3622
USAT: +1 215 488-9300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
14
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.40 | 16.50 | -0.19% |
| CAC 40 | 7,606.17 | 49.95 | -0.65% |
| DAX 40 | 23,174.85 | 142.96 | -0.61% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,808.18 | 35.29 | -0.40% |
| HKSE | 23,243.14 | 467.55 | -1.97% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,488.34 | 396.81 | -1.02% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,523.70 | 7.50 | -0.09% |
| SSE Composite Index | 3,362.11 | 26.70 | -0.79% |